1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies by Di Pietro, O. et al.
                             Elsevier Editorial System(tm) for European Journal of Medicinal Chemistry 
                                  Manuscript Draft 
 
 
Manuscript Number: EJMECH-D-13-01920R1 
 
Title: 1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-
midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and 
mechanistic studies  
 
Article Type: Full Length Article 
 
Keywords: benzo[h][1,6]naphthyridines; Povarov reaction; dual inhibitors; AChE PAS; AChE midgorge 
binding 
 
Corresponding Author: Prof. Diego Muñoz-Torrero, Doctor in Pharmacy 
 
Corresponding Author's Institution: University of Barcelona 
 
First Author: Diego Muñoz-Torrero, Doctor in Pharmacy 
 
Order of Authors: Diego Muñoz-Torrero, Doctor in Pharmacy; Ornella Di Pietro, PhD student; Elisabet 
Viayna, Dr.; Esther Vicente-García, Dr.; Manuela Bartolini, Dr.; Rosario Ramón, Dr.; Jordi Juárez-
Jiménez, PhD student; M. Victòria Clos, Dr.; Belén Pérez, Dr.; Vincenza Andrisano, Dr.; F. Javier Luque, 
Dr.; Rodolfo Lavilla, Dr. 
 
Abstract: A series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines differently substituted at positions 
1, 5, and 9 have been designed from the pyrano[3,2-c]quinoline derivative 1, a weak inhibitor of 
acetylcholinesterase (AChE) with predicted ability to bind to the AChE peripheral anionic site (PAS), at 
the entrance of the catalytic gorge. Fourteen novel benzonaphthyridines have been synthesized 
through synthetic sequences involving as the key step a multicomponent Povarov reaction between an 
aldehyde, an aniline and an enamine or an enamide as the activated alkene. The novel compounds have 
been tested against Electrophorus electricus AChE (EeAChE), human recombinant AChE (hAChE), and 
human serum butyrylcholinesterase (hBChE), and their brain penetration has been assessed using the 
PAMPA-BBB assay. Also, the mechanism of AChE inhibition of the most potent compounds has been 
thoroughly studied by kinetic studies, a propidium displacement assay, and molecular modelling. We 
have found that a seemingly small structural change such as a double O → NH bioisosteric replacement 
from the hit 1 to 16a results in a dramatic increase of EeAChE and hAChE inhibitory activities (>217- 
and >154-fold, respectively), and in a notable increase in hBChE inhibitory activity (> 11-fold), as well. 
An optimized binding at the PAS besides additional interactions with AChE midgorge residues seem to 
account for the high hAChE inhibitory potency of 16a (IC50 = 65 nM), which emerges as an interesting 
anti-Alzheimer lead compound with potent dual AChE and BChE inhibitory activities. 
 
 
 
 
 1 
1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of 
potent peripheral-to-midgorge-site inhibitors of 
acetylcholinesterase: synthesis, pharmacological evaluation and 
mechanistic studies 
 
Ornella Di Pietro
a
, Elisabet Viayna
a
, Esther Vicente-García
b
, Manuela 
Bartolini
c
, Rosario Ramón
b
, Jordi Juárez-Jiménez
d
, M. Victòria Clos
e
, 
Belén Pérez
e
, Vincenza Andrisano
f
, F. Javier Luque
d
, Rodolfo Lavilla
b,g,*
, 
Diego Muñoz-Torrero
a,**
 
 
a
 Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de 
Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Joan 
XXIII, 27-31, E-08028, Barcelona, Spain 
b
 Barcelona Science Park, Baldiri Reixac 10-12, E-08028, Barcelona, Spain 
c
 Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of 
Bologna, Via Belmeloro 6, I-40126, Bologna, Italy 
d
 Departament de Fisicoquímica, Facultat de Farmàcia, and IBUB, Universitat de 
Barcelona, Prat de la Riba 171, E-08921, Santa Coloma de Gramenet, Spain 
e
 Departament de Farmacologia, de Terapèutica i de Toxicologia, Institut de 
Neurociències, Universitat Autònoma de Barcelona, E-08193, Bellaterra, Barcelona, 
Spain 
f
 Department for Life Quality Studies, University of Bologna, Corso d’Augusto 237, I-
47921, Rimini, Italy 
g
 Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, 
Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain 
 
 
 
* Corresponding author. Tel.: +34 934037106; fax: +34 934024539. 
** Corresponding author. Tel.: +34 934024533; fax: +34 934035941. 
E-mail addresses: rlavilla@pcb.ub.es (R. Lavilla), dmunoztorrero@ub.edu (D. Muñoz-
Torrero). 
*Revised Manuscript
Click here to view linked References
 2 
ABSTRACT 
A series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines differently substituted at 
positions 1, 5, and 9 have been designed from the pyrano[3,2-c]quinoline derivative 1, a 
weak inhibitor of acetylcholinesterase (AChE) with predicted ability to bind to the 
AChE peripheral anionic site (PAS), at the entrance of the catalytic gorge. Fourteen 
novel benzonaphthyridines have been synthesized through synthetic sequences 
involving as the key step a multicomponent Povarov reaction between an aldehyde, an 
aniline and an enamine or an enamide as the activated alkene. The novel compounds 
have been tested against Electrophorus electricus AChE (EeAChE), human 
recombinant AChE (hAChE), and human serum butyrylcholinesterase (hBChE), and 
their brain penetration has been assessed using the PAMPA-BBB assay. Also, the 
mechanism of AChE inhibition of the most potent compounds has been thoroughly 
studied by kinetic studies, a propidium displacement assay, and molecular modelling. 
We have found that a seemingly small structural change such as a double O → NH 
bioisosteric replacement from the hit 1 to 16a results in a dramatic increase of EeAChE 
and hAChE inhibitory activities (>217- and >154-fold, respectively), and in a notable 
increase in hBChE inhibitory activity (> 11-fold), as well. An optimized binding at the 
PAS besides additional interactions with AChE midgorge residues seem to account for 
the high hAChE inhibitory potency of 16a (IC50 = 65 nM), which emerges as an 
interesting anti-Alzheimer lead compound with potent dual AChE and BChE inhibitory 
activities. 
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1. Introduction 
Alzheimer’s disease (AD) is a progressive and ultimately fatal neurodegenerative 
disorder that is currently threatening every health system worldwide. The number of 
people with AD increases rapidly, and in line with this, both prevalence and costs are 
also increasing [1]. Currently, it is estimated that dementia, of which AD is the most 
common type, is affecting 36 million people, with a total cost amounting to as much as 
1% of global gross domestic product [1]. AD is among the top ten causes of death, but, 
worryingly, the only one that cannot be prevented, cured or slowed down [2], thereby 
making it imperative the development of efficacious drugs. 
Current therapeutic options, i.e. the acetylcholinesterase (AChE) inhibitors donepezil, 
galantamine and rivastigmine and the glutamate NMDA receptor antagonist memantine, 
are regarded as merely symptomatic, and very promising -amyloid (A)-directed drug 
candidates designed to confront the underlying mechanisms of AD are inexorably 
failing in late stage clinical trials due to lack of efficacy or safety. The increasingly 
accepted notion that A is not the cause but one of the causes of AD [3] is spurring the 
development of multi-target drugs that simultaneously hit A formation and aggregation 
as well as other important targets such as tau hyperphosphorylation and aggregation, 
oxidative stress and cholinesterases, among others, as a more realistic option to 
effectively treat AD [4]. 
In every case, any single-target or multi-target drug candidate purported to modify AD 
progression would need to be administered in the early presymptomatic or preclinical 
stage of AD, before neurodegeneration is too widespread. Indeed, preclinical AD has 
been proposed as the initial stage of AD in the new criteria and guidelines for 
diagnosing AD [2]. Accurate and reliable biomarkers, indicative of the earliest signs of 
the disease, are necessary both to identify individuals in the presymptomatic stage of 
AD, amenable to early interventions with disease-modifying drugs and to monitor their 
effects. Many research endeavours are being made to select the best diagnostic 
biomarkers or combinations thereof [5] but much more work is still needed before 
preclinical AD can be diagnosed [2]. Meanwhile, diagnosis of AD will remain based on 
symptoms, i.e. on the occurrence of cognitive decline, for whose alleviation AChE 
inhibitors (AChEIs) are the best therapeutic option [6], thereby warranting the search 
for novel AChEIs. 
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Most known AChEIs have been designed to interact with the catalytic site of the 
enzyme, which is placed at the bottom of a 20 Å deep narrow gorge. The entrance of the 
gorge contains the so-called peripheral anionic site (PAS) [7], which can be also 
targeted either separately or simultaneously by potential inhibitors [8]. Recently, we 
have developed a new family of AChEIs that consisted of a pyrano[3,2-c]quinoline 
moiety connected through linkers of different lengths to a unit of the potent active site 
AChEI 6-chlorotacrine [9]. Among those hybrids, the most potent human AChE 
(hAChE) inhibitors bore a 5-(4-chlorophenyl)pyrano[3,2-c]quinoline moiety, which is 
present in their synthetic ester precursor 1 (Fig. 1) and is reminiscent to the phenyl-
substituted tricyclic system of the AChE PAS inhibitor propidium (2, Fig. 1). Not 
unexpectedly, molecular dynamics simulations suggested that the 5-(4-
chlorophenyl)pyrano[3,2-c]quinoline moiety of the hybrids interacts at the PAS of 
AChE, namely by establishing – stacking interactions with residues Trp286 and 
Tyr72 (hAChE numbering), whereas the 6-chlorotacrine unit interacts with the active 
site residues Trp86 and Tyr337. Strikingly, despite the predicted ability of the 5-(4-
chlorophenyl)pyrano[3,2-c]quinoline moiety to interact with the AChE PAS, compound 
1 was found to be essentially inactive as inhibitor of hAChE (IC50 > 10 μM). 
In the light of these results, we inferred that substitution of the oxygen atom at position 
1 of the pyrano[3,2-c]quinoline system of 1 by a nitrogen atom would result in 
increased basicity of the quinoline nitrogen atom, which would become protonatable at 
physiological pH. This would enable the resulting benzo[h][1,6]naphthyridine system to 
establish cation– interactions additionally to the – stacking, thereby potentially 
increasing its affinity for the PAS of AChE and the AChE inhibitory activity. These 
interactions would be similar to those established by the phenanthridinium system of 
propidium, but unlike propidium, the non-permanent character of the positive charge at 
the quinoline nitrogen atom of the benzo[h][1,6]naphthyridine system would not 
preclude their penetration into the central nervous system (CNS). 
Herein, we describe the synthesis, cholinesterase inhibitory activity evaluation and a 
comprehensive assessment of the binding mode to AChE by kinetic, propidium 
displacement and molecular modelling studies of a series of 1,2,3,4-
tetrahydrobenzo[h][1,6]naphthyridines differently substituted at positions 1, 5, and 9. 
Moreover, the brain penetration of these compounds has been assessed using the 
parallel artificial membrane permeation assay (PAMPA-BBB). 
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2. Results and discussion 
2.1. Synthesis of the target compounds 
To assess the effect on cholinesterase inhibitory activity of substitution at position 1, we 
initially planned the synthesis of 1,2,3,4-benzo[h][1,6]naphthyridines bearing an ethyl 
ester group at position 9 and a 4-chlorophenyl substituent at position 5, like in the 
pyrano[3,2-c]quinoline analogue 1, and either a benzyl group (10a), hydrogen atom 
(12a) or a 4-methoxybenzyl group (13a) on the nitrogen atom at position 1 (Scheme 1). 
Also, to ascertain the effect of the substituent at position 5, we planned the synthesis of 
the 1-benzylated ethyl ester analogues bearing a 3-pyridyl (10b) or 4-
methoxycarbonylphenyl (10c) substituent at position 5. Finally, to shed light on the role 
of the substituent at position 9, we studied the substitution of the ethyl carboxylic ester 
group of 10a by an N-ethyl carboxamide (14a) and an ethylaminomethyl (17a) group. 
Following the evaluation of the AChE inhibitory activity of this first generation of 
1,2,3,4-benzo[h][1,6]naphthyridine derivatives and the establishment of structure–
activity relationships, we additionally envisioned the synthesis of compounds 12b, 16a, 
18a, and 18b (Scheme 1) as second generation optimized analogues (see below). 
The synthesis of compounds 10a–c was envisaged out through a three-step sequence 
involving an initial Povarov multicomponent reaction [10] between the known cyclic 
enamide 3 [11], as the activated alkene, ethyl 4-aminobenzoate, 5, and the aromatic 
aldehydes 4a–c, under Sc(OTf)3 catalysis in acetonitrile (Scheme 1). These reactions 
afforded in moderate to good yields and 1:1 to 1.7:1 diastereomeric ratio the 
diastereomeric mixtures of cis-fused octahydronaphthyridines 6a–c, which were 
subjected to DDQ oxidation [12] to yield the lactams 9a–c in 73%, 5%, and 36% yield, 
respectively, after silica gel column chromatography purification. In an attempt to 
improve the yield of 9b, the oxidation of the mixture 6b with MnO2 [13] instead of 
DDQ only afforded unreacted material and open-ring byproducts. Chemoselective 
reduction of lactams 9a–c with (EtO)3SiH under Zn(OAc)2 catalysis [14] provided the 
desired benzonaphthyridines 10a–c in low to moderate (15–52%) yields. 
Analogously, the Povarov reaction of aniline 5, aldehydes 4a,b and the commercially 
available N-Boc-protected cyclic enamine 7, followed by DDQ or MnO2 oxidation of 
the resulting diastereomeric mixtures 8a,b afforded the N-Boc-protected derivatives 11a 
and 11b in 57% and 24% overall yields (Scheme 1). Acidic deprotection of 11a 
quantitatively yielded the target benzonaphthyridine 12a, which was also used as 
starting material for the synthesis of the 1-(4-methoxybenzyl)-substituted 
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benzonaphthyridine 13a (40% yield) by deprotonation with NaH and alkylation with 1-
chloromethyl-4-methoxybenzene. In turn, acidic deprotection of 11b afforded the target 
benzonaphthyridine 12b in 76% yield. 
Derivatization at position 9 was carried out following standard procedures. Thus, ethyl 
carboxylic esters 10a, 11a and 12b were converted into the corresponding N-
ethylcarboxamides 14a, 15a and 16b, respectively, in moderate overall yields, by 
alkaline hydrolysis followed by reaction of the resulting carboxylic acids, isolated as 
naphthyridine hydrochlorides, with ethyl chloroformate in the presence of Et3N, and 
reaction of the mixed anhydrides with ethylamine (Scheme 1). Finally, LiAlH4 
reduction of the amides 14a and 16b afforded the amines 17a and 18b in 44% and 51% 
yields, respectively, whereas reaction of the N-Boc-protected amide 15a with LiAlH4 
proceeded with both N-Boc-deprotection and reduction of the amide, directly affording 
the target N-Boc-deprotected benzonaphthyridine 18a in 35% yield, together with a 
small amount of the N-Boc-deprotected amide 16a (14% yield). 
 
 2.2. Biological activity assays 
The inhibitory activity of the novel 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines 
against Electrophorus electricus AChE (EeAChE) and human recombinant (hAChE) 
was evaluated by the method of Ellman et al. [15]. Another cholinesterase that seems to 
play an important role in the cognitive decline associated to AD is butyrylcholinesterase 
(BChE). BChE exerts a compensatory effect in response to the decrease of AChE in 
CNS as AD progresses, thereby making dual inhibition of AChE and BChE a desirable 
property for anti-Alzheimer drugs [16]. Thus, the inhibitory activity of these compounds 
against human serum BChE (hBChE) was determined as well [15]. 
In general, the novel first-generation benzonaphthyridines were found to be moderately 
potent inhibitors of EeAChE, with IC50 values ranging from the submicromolar to the 
low micromolar range (Table 1). The best substitution pattern at position 1 clearly 
involves the presence of an unsubstituted secondary amino group, compound 12a being 
23- and >107-fold more potent EeAChE inhibitor than the N-benzylated and N-(4-
methoxy)benzylated counterparts 10a and 13a, respectively. With the sole exception of 
12a, the rest of first generation benzonaphthyridines are N-benzylated derivatives, 
among which two additional structure–activity relationship (SAR) trends leading to a 
higher EeAChE inhibitory activity could be derived, namely the presence of a 3-pyridyl 
and an ethylaminomethyl substituent at positions 5 and 9, respectively. Thus, the 5-(3-
 7 
pyridyl)-substituted ester 10b is 3-fold more potent that its 5-(4-chlorophenyl)- and 5-
(4-methoxycarbonylphenyl)-substituted analogues 10a and 10c, whereas the 
benzonaphthyridine 17a, bearing an amine functionality in the side chain at position 9, 
is about 40-fold more potent than the ester and amide derivatives 10a and 14a (Table 1). 
Not unexpectedly, the benzonaphthyridines 10b,c are more potent EeAChE inhibitors 
than their less basic lactam precursors 9b,c (>15- and 2-fold, respectively), with the 
exception of compounds 10a and 9a, which were roughly equipotent.  
In the light of the SAR derived from the first-generation benzonaphthyridines, starting 
from 10a we designed a second generation of analogues bearing simultaneously several 
or all of the structural features that were found to lead to higher EeAChE inhibitory 
activity, all of them N-debenzylated at position 1 and additionally bearing either a 3-
pyridyl group at position 5 (12b) or an ethylaminoethyl chain at position 9 (18a) or both 
groups (18b). To further explore the role of N-debenzylation at position 1, compound 
16a, the debenzylated analogue of the amide 14a, was also included among the second 
generation benzonaphthyridines. 
With the exception of 18a, which is 4-fold less potent than its N-benzylated analogue 
17a, the second-generation N-debenzylated benzonaphthyridines 12b and 16a were 
clearly more potent than their N-benzylated counterparts 10b and 14a (13- and 119-fold, 
respectively). However, the two SAR trends seen for the first-generation N-benzylated 
benzonaphthyridines were not apparent in the second-generation N-debenzylated 
analogues, in which the presence of a 4-chlorophenyl group at position 5 and an amide 
functionality at the side chain in position 9 were the structural features leading to an 
optimal EeAChE inhibitory activity. These results seem to suggest a different 
orientation of the N-benzylated and N-debenzylated compounds within EeAChE. 
Worthy of note, divergent SARs and binding modes of the PAS-binding moiety of two 
similar structural classes of inhibitors featuring small changes in their aromatic rings 
have been recently reported [17]. 
Overall, amide 16a turned out to be the most potent benzonaphthyridine of the whole 
series as EeAChE inhibitor, exhibiting a nanomolar IC50 value (46 nM). 
When tested on hAChE, significant inter-species differences relative to EeAChE were 
found in some cases, even though similar general SAR trends were observed. Thus, 
benzonaphthyridines bearing an amide or an amine functionality in the side chain at 
position 9 were found to be potent inhibitors, with IC50 values in the submicromolar 
range in all cases except for the 5-(3-pyridyl)-substituted derivative 18b, whereas most 
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ester derivatives were weakly active (Table 1). Among the most potent derivatives, the 
higher hAChE inhibitory activity was associated to the presence of an unsubstituted 
secondary amino group at position 1 (16a and 18a being 12- and 2-fold more potent 
than 14a and 17a), an amide at position 9 (14a and 16a being 1.2- and 9-fold more 
potent than the amines 17a and 18a) and a 4-chlorophenyl substituent at position 5 (18a 
being 28-fold more potent than 18b). Again, benzonaphthyridine 16a turned out to be 
the most interesting compound of the series, emerging as a very potent inhibitor of 
hAChE (IC50 65 nM). Noteworthy, 16a is 500-fold more potent than the specific PAS 
inhibitor propidium and 6-fold more potent than the active site inhibitor tacrine, the 
second most potent hAChEI among the approved anti-Alzheimer drugs. 
Regarding the inhibition of hBChE, most compounds displayed very weak inhibitory 
activity (4–28% inhibition at 30 μM). Interestingly, the N-debenzylated amide or amine 
derivatives 16a, 18a, and 18b were found to be more potent inhibitors of hBChE, with 
IC50 values around 1–3 μM (Table 1), they being more potent than propidium but less 
potent than tacrine. 
Inhibition of A aggregation is another valuable property for anti-Alzheimer 
compounds, which is additionally investigated in many cholinesterase inhibitors [19]. 
Unfortunately, these benzonaphthyridines turned out to be rather weak inhibitors of 
A42 self-aggregation, displaying percentages of inhibition up to 16% at 10 μM (data 
not shown). 
Overall, benzonaphthyridine 16a emerges as a promising anti-Alzheimer agent, by 
virtue of its dual potent hAChE and hBChE inhibitory activities. Because interactions of 
ligands at the PAS of AChE are not as tight as those that can be established at the active 
site, peripheral site AChEIs do not usually display high affinities and potencies [20]. 
Thus, the potent hAChE inhibitory activity of some of the benzonaphthyridines, 
particularly 16a, which were designed as peripheral site AChEIs, was somehow 
astonishing. To shed light on the binding mode of these compounds within AChE, a set 
of mechanistic studies was performed, encompassing kinetic experiments (Lineweaver-
Burk and Cornish-Bowden plots), propidium displacement assay, and molecular 
modelling studies (docking and molecular dynamics simulations, and Solvated 
Interaction Energy calculations). 
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2.3. Kinetic studies 
To investigate the mode of inhibition of the most active AChEI benzonaphthyridine, 
16a, and its N-benzylated analogue 14a, Lineweaver-Burk double reciprocal plots were 
generated. The interception of the lines in the Lineweaver-Burk plot above the x-axis 
(Fig. 2) demonstrated that both compounds serve as mixed-type inhibitors of AChE. 
Mixed-type of inhibition was further confirmed by Cornish-Bowden plots (S/v versus 
[I]) [21]. 
The inhibition constant (Ki) and the K’i (dissociation constant for the enzyme–substrate–
inhibitor complex) estimated for 14a were 0.785 μM and 2.34 μM, respectively, and for 
16a were 0.065 μM and 0.073 μM, respectively. These findings show that introduction 
of a benzyl substituent at position 1 decreases the affinity not only for the enzyme active 
site (12-fold higher dissociation constant of the EI complex) but likely also for the PAS 
(32-fold higher K’i value). Moreover, the similar values of Ki and K’i found for 16a 
suggest that the high inhibitory potency of this compound might arise from the ability to 
tightly bind both sites, and not only at the PAS. 
To get further insights into the mechanism of inhibition and confirm the ability to 
interact with the AChE PAS, the affinity of the four most interesting derivatives (14a, 
16a, 17a, and 18a) for the PAS of AChE was investigated by displacement studies with 
propidium iodide, using the method of Taylor et al. [22]. Propidium selectively 
associates with the PAS of AChE exhibiting an eight-fold enhancement of fluorescence 
[22a,23]. Back-titration experiments with increasing concentration of all selected 
compounds but 14a showed a concentration-dependent decrease in the fluorescence 
intensity associated with the propidium–AChE complex, suggesting that they can 
effectively displace propidium from the AChE’s PAS (Fig. 3A). Solubility of 14a in the 
assay conditions was insufficient to allow a full back-titration experiment. At 1/1 ratio 
with propidium iodide 14a was able to reduce fluorescence intensity associated with the 
AChE–propidium complex by only 5%, confirming a lower affinity for the PAS than 
the N-debenzylated analogue 16a, as also suggested by the K’i values. In general, the 
affinity trend was 16a > 18a > 17a with concentrations required for decreasing initial 
fluorescence intensity of AChE–propidium complex ([propidium] = 8 µM) equal to 13, 
23, and 33 µM, respectively. 
Back-titration experiments for the most active derivative in the series, 16a, predicted a 
dissociation constant of 1.76 μM (Fig. 3B). This value is consistent with a quite tight 
binding to the PAS, only 2.5-fold weaker than that of propidium (KD on EeAChE = 0.7 
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µM [23]). Values for the other tested analogues were slightly higher, being 2.18 and 
3.20 µM for 18a and 17a, respectively. The slightly lower value obtained for the N-
benzylated derivative, 17a, further confirms an unfavorable effect of the benzyl 
substituent at position 1. 
 
2.4. Molecular modelling studies 
The binding of compounds 16a and 18a to hAChE (Fig. 4) was firstly explored by 
docking calculations carried out with rDock [24]. It is worth noting that previous studies 
strongly support the performance of this docking program for predicting the binding 
mode of a number of AChE inhibitors to the enzyme [9]. Docking was performed using 
three models of hAChE that differ in the orientation of Trp286, which was arranged to 
reflect the three major conformations adopted by this residue upon inspection of the 
available X-ray crystallographic structures (see Experimental part) [25]. 
The docking results revealed a preferential binding to the AChE model where Trp286 
retains the orientation found in the AChE–propidium complex (PDB ID 1N5R [20b]). 
This finding is not unexpected keeping in mind the size of the heteropolycyclic ring 
system present in compounds 16a and 18a and in propidium. Thus, a distinctive binding 
mode was clearly identified on the basis of the most populated cluster of docked poses 
and the docking score, where the 5-(4-chlorobenzyl) substituent of 16a and 18a stacks 
against the indole ring of Trp286 and the CONHEt (16a) and CH2NH2Et (18a) 
substituents penetrate along the gorge towards the catalytic site. 
A 100 ns MD simulation was run to refine the binding mode of compounds 16a and 
18a. Simulations yielded structurally and energetically stable trajectories, which showed 
an initial rearrangement of the ligand without significant alterations in the residues that 
shape the binding site (see Fig. S1 in Supplementary material). The results obtained for 
compound 16a point out that the central pyridine ring of the benzonaphthyridine system 
stacks against Trp286 (average distance of 3.74 Å; Fig. 4A), thus enabling the cation- 
interaction between the protonated pyridine nitrogen atom of 16a and the indole system 
of Trp286. Furthermore, binding is assisted by the formation of hydrogen bonds 
between the pyridine nitrogen atom and the hydroxyl group of Tyr72 (average distance 
of 3.20 Å) and between the amide NH group and the hydroxyl group of Tyr124 
(average distance of 3.17 Å). Compared to 16a, binding of 18a involves the formation 
of a water-mediated bridge between the protonated amine of the side chain at position 9 
and Asp72 (average distance of 5.9 Å) and a cation-π interaction with the benzene ring 
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of Tyr341 (average distance of 3.54 Å), besides the cation-π interaction with Trp286. 
Finally, the NH group at position 1 forms water-mediated hydrogen bonds with the 
carbonyl groups of Ser293 and Phe338. Clearly, the similar binding mode of 
compounds 16a and 18a (Fig. 4B) must be drastically perturbed by the attachment of 
the N-benzyl group at position 1 due to the steric clash with the neighbouring residues, 
which likely explains the weaker potency measured for compounds 14a and 17a. 
Overall, MD simulations show that compounds 16a and 18a are capable of forming a 
network of diverse interactions with residues at the PAS and midgorge sites. 
To further validate the binding mode of 16a and 18a, the binding affinities were 
determined using the Solvated Interaction Energy (SIE) calculations. The SIE method 
relies on MM/PBSA calculations of the ligand–receptor complex, but the free energy 
components are weighted by a scaling factor parametrized to reproduce the 
experimental binding affinities for a diverse set of protein–ligand complexes [26]. The 
predicted binding affinities for 16a and 18a are 8.5  0.4 and 8.8  0.6 kcal/mol (see 
Table S1 in Supplementary material), which compare with the experimental value 
determined from the inhibition constant for 16a (9.7 kcal/mol). Thus, within the 
uncertainty of the SIE method, the predicted binding affinities reflect the similar 
inhibitory potency of 16a and 18a. Since they exhibit a similar binding mode, it can be 
concluded that the large desolvation penalty of the protonated amine present in the side 
chain at position 9 counterbalances the enhanced coulombic stabilization found for 18a, 
the net effect leading to an inhibitory potency close to the potency of the amide 
derivative 16a. 
 
2.5. Blood–brain barrier permeation assay 
Brain penetration is an essential property for every anti-Alzheimer drug candidate. The 
ability of the synthesized benzonaphthyridines to cross the blood–brain barrier (BBB) 
and therefore to reach the CNS was assessed using the known parallel artificial 
membrane permeation assay (PAMPA-BBB) as an in vitro model of passive 
transcellular permeation [27]. The in vitro permeability (Pe) of the novel 1,2,3,4- 
benzo[h][1,6]naphthyridines through a lipid extract of porcine brain was determined 
using a mixture of phosphate-buffered saline (PBS)/EtOH (70:30). Assay validation was 
carried out by comparison of the experimental and reported permeability values of 14 
commercial drugs (see Table S2 in Supplementary Material), which provided a good 
linear correlation: Pe (exp) = 1.4974 Pe (lit) – 0.8434 (R
2
 = 0.9428). Using this equation 
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and the limits established by Di et al. for BBB permeation [27], the following ranges of 
permeability were established:  Pe (10
6
 cm s
1
) > 5.1 for compounds with high BBB 
permeation (CNS+); Pe (10
6
 cm s
1
) < 2.15 for compounds with low BBB permeation 
(CNS); and 5.1 > Pe (10
6
 cm s
1
) > 2.15 for compounds with uncertain BBB 
permeation (CNS+/). All the tested benzonaphthyridines were predicted to be able to 
cross the BBB, with the exception of amine 18b, for which an uncertain brain 
penetration was predicted. Indeed, amines 18b and 18a, whose permeability value was 
near the minimum threshold for high BBB permeation, seemed to be the most polar 
benzonaphthyridines of the series, which, as mentioned above might account for the 
apparently high desolvation penalty detrimental for their AChE inhibitory potencies. 
 
3. Conclusion 
We have carried out the optimization of the AChE PAS-binding affinity of the initial hit 
1, ethyl 5-(4-chlorophenyl)-3,4-dihydro-2H-pyrano[3,2-c]quinoline-9-carboxylate, 
neutral at physiological pH, by replacement of the oxygen atom at position 1 by a 
nitrogen atom [of a N–H, N-benzyl or N-(4-methoxybenzyl) group]. The main aim of 
this structural change was to increase the basicity, and therefore the protonation ability, 
of the resulting 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine derivatives, thereby 
making it possible the establishment of cation- interactions besides - stacking with  
the PAS residue Trp286. Moreover, the effect on the AChE inhibitory activity of 
replacements of the 4-chlorophenyl and ethyl carboxylate groups at positions 5 and 9, 
present in 1, by 4-(methoxycarbonyl)phenyl or 3-pyridyl groups at position 5 and by N-
ethylcarboxamido or ethylaminomethyl groups at position 9 were investigated to 
explore potential additional interactions nearby the PAS. Despite some significant inter-
species differences, the substitution pattern leading to a higher inhibitory activity both 
in EeAChE and hAChE involves the presence of a debenzylated nitrogen atom at 
position 1, and 4-chlorophenyl and N-ethylcarboxamido groups at positions 5 and 9, 
respectively. Overall, the hit-to-lead optimization process from 1 to 16a simply involves 
a double bioisosteric O → NH replacement at position 1 and in the side chain at 
position 9, but results in a dramatic increase in EeAChE (>217-fold) and hAChE (>154-
fold) inhibitory activities. Interestingly, such a change also leads to a noticeable increase 
in hBChE inhibitory activity (>11-fold). Because most AChE PAS inhibitors exhibit 
potencies in the micromolar range, the very potent hAChE inhibitory activity of the lead 
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16a (IC50 = 65 nM) might arise from additional interactions other than those established 
with PAS residues, as supported by the results derived from a comprehensive 
mechanistic study. On the one hand, kinetic studies and propidium displacement studies 
have confirmed the ability of 16a to tightly bind the AChE PAS. On the other hand, 
molecular modelling studies have suggested the ability of the heteroaromatic system of 
16a to establish cation- and - interactions with the PAS residue Trp286 but also the 
ability of the amide functionality at position 9 to penetrate along the gorge towards the 
catalytic site and to establish additional hydrogen bond interactions with AChE 
midgorge residues. The tight binding of 16a to the AChE PAS and the additional 
midgorge interactions seem to account for its very potent hAChE inhibitory activity. 
Overall, the potent dual hAChE and hBChE inhibitory activities of 16a make it a very 
interesting anti-Alzheimer lead compound.  
 
 4. Experimental part 
4.1. Chemistry. General methods.  
Melting points were determined in open capillary tubes with a MFB 595010M 
Gallenkamp melting point apparatus. 400 MHz 
1
H/100.6 MHz 
13
C NMR spectra were 
recorded on a Varian Mercury 400 spectrometer. The chemical shifts are reported in 
ppm (δ scale) relative to internal tetramethylsilane, and coupling constants are reported 
in Hertz (Hz). Assignments given for the NMR spectra of the new compounds have 
been carried out by comparison with the NMR data of 9c, 10c, 11a, 17a, and 18b, 
which in turn, were assigned on the basis of DEPT, COSY 
1
H/
1
H (standard procedures), 
and COSY 
1
H/
13
C (gHSQC or gHMBC sequences) experiments. IR spectra were run on 
a Perkin-Elmer Spectrum RX I or on a Thermo Nicolet Nexus spectrophotometer. 
Absorption values are expressed as wave-numbers (cm
1
); only significant absorption 
bands are given. Column chromatography was performed on silica gel 60 AC.C (3570 
mesh, SDS, ref 2000027). Thin-layer chromatography was performed with aluminum-
backed sheets with silica gel 60 F254 (Merck, ref 1.05554), and spots were visualized 
with UV light and 1% aqueous solution of KMnO4. NMR spectra of all of the new 
compounds were performed at the Centres Científics i Tecnològics of the University of 
Barcelona (CCiTUB), while elemental analyses and high resolution mass spectra were 
carried out at the Mycroanalysis Service of the IIQAB (CSIC, Barcelona, Spain) with a 
Carlo Erba model 1106 analyzer, and at the CCiTUB with a LC/MSD TOF Agilent 
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Technologies spectrometer, respectively. The HPLC measurements were performed 
using a HPLC Waters Alliance HT apparatus comprising a pump (Edwards RV12) with 
degasser, an autosampler, a diode array detector and a column as specified below. The 
reverse phase HPLC determinations were carried out on a YMC-Pack ODS-AQ column 
(50×4.6 mm,  D S. 3 μm, 12 nm). Solvent A: water with 0.1% formic acid; Solvent B: 
acetonitrile with 0.1% formic acid. Gradient: 5% of B to 100% of B within 3.5 min. 
Flux: 1.6 mL/min at 50 ºC. The analytical samples of all of the compounds that were 
subjected to pharmacological evaluation were dried at 65 ºC / 2 Torr (standard 
conditions) and possess a purity 95% as evidenced by their elemental analyses and/or 
HPLC measurements. The synthetic procedures for the preparation of the intermediate 
and target compounds are exemplified through the synthesis of the most potent 
compound of the series, 16a. The synthesis of the rest of compounds is included in the 
Supplementary Material.   
 
4.1.1. Ethyl 1-(tert-butoxycarbonyl)-5-(4-chlorophenyl)-1,2,3,4,4a,5,6,10b-
octahydrobenzo[h][1,6]naphthyridine-9-carboxylate, diastereomeric mixture 8a 
To a stirred solution of p-chlorobenzaldehyde, 4a (1.36 g, 9.67 mmol) and ethyl 4-
aminobenzoate, (1.60 g, 9.69 mmol) in anhydrous CH3CN (25 mL), 4 Å molecular 
sieves and Sc(OTf)3 (0.95 g, 1.93 mmol) were added. The mixture was stirred at room 
temperature under argon atmosphere for 5 min and then treated with a solution of 
enamine 7 (1.80 mL, 1.78 g, 9.70 mmol) in anhydrous CH3CN (12 mL). The resulting 
suspension was stirred at room temperature under argon atmosphere for 3 days. Then, 
the resulting mixture was diluted with sat. aq. NaHCO3 (150 mL) and extracted with 
EtOAc (3  200 mL). The combined organic extracts were dried over anhydrous 
Na2SO4, filtered and evaporated under reduced pressure to give a solid residue (4.75 g), 
which was purified by column chromatography (35–70 μm silica gel, hexane/EtOAc 
mixtures, gradient elution). On elution with hexane/EtOAc 80:20 to 70:30, the 
diastereomeric mixture 8a (2.86 g, 63% yield, 3:1 diastereomeric ratio (
1
H NMR)) was 
isolated as a white solid. 
 
4.1.2. Ethyl 1-(tert-butoxycarbonyl)-5-(4-chlorophenyl)-1,2,3,4-
tetrahydrobenzo[h][1,6]naphthyridine-9-carboxylate 11a 
To a solution of diastereomeric mixture 8a (1.41 g, 2.99 mmol) in anhydrous CHCl3 (37 
mL), DDQ (1.36 g, 5.99 mmol) was added. The reaction mixture was stirred at room 
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temperature under argon atmosphere overnight, diluted with CH2Cl2 (150 mL) and 
washed with sat. aq. NaHCO3 (3  200 mL). The combined organic extracts were dried 
over anhydrous Na2SO4, filtered and evaporated under reduced pressure to give an 
orange solid residue (1.46 g), which was purified through column chromatography (35–
70 μm silica gel, hexane/EtOAc mixtures, gradient elution). On elution with 
hexane/EtOAc 80:20, compound 11a (1.25 g, 90% yield) was isolated as a white solid; 
Rf 0.61 (hexane/EtOAc 1:1). 
A solution of 11a (100 mg, 0.21 mmol) in CH2Cl2 (8 mL) was filtered through a 0.2 μm 
PTFE filter and evaporated at reduced pressure. The solid was washed with pentane (3  
4 mL) to give, after drying under standard conditions, the analytical sample of 11a (97 
mg): mp 154–155 °C (CH2Cl2); IR (KBr) ν 1713, 1697 (C=O st), 1618, 1592, 1577, 
1566 (ArCC and ArCN st) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.39 [s, 9H, 
C(CH3)3], 1.43 (t, J=7.2 Hz, 3H, CO2CH2CH3), 2.00 (br signal, 2H, 3-H2), 2.80 (m, 2H, 
4-H2), 3.203.60 (br signal, 2H, 2-H2), 4.45 (q, J=7.2 Hz, 2H, CO2CH2CH3), 7.48 [ddd, 
J=8.4 Hz, J’≈J”≈2.0 Hz, 2H, 5ArC3(5)-H], 7.55 [ddd, J≈8.4 Hz, J’≈J”≈2.0 Hz, 2H, 
5ArC2(6)-H], 8.08 (d, J≈8.8 Hz, 1H, 7-H), 8.24 (dd, J=8.8 Hz, J’=1.6 Hz 1H, 8-H), 
8.59 (d, J=1.6 Hz, 1H, 10-H); 
13
C NMR (100.6 MHz, CDCl3) δ 14.3 (CH3, 
CO2CH2CH3), 24.1 (CH2, C3), 25.4 (CH2, C4), 27.9 [3CH3, C(CH3)3], 44.7 (CH2, C2), 
61.3 (CH2, CO2CH2CH3), 82.1 [C, C(CH3)3], 122.9 (C, C10a), 123.8 (C, C4a), 127.0 (C, 
C9), 127.6 (CH, C10), 128.2 (CH, C8), 128.6 [2CH, 5ArC3(5)], 129.7 (CH, C7), 
130.3 [2CH, 5ArC2(6)], 134.8 (C, 5ArC4), 138.3 (C, 5ArC1), 145.7 (C, C10b), 
148.8 (C, C6a), 153.9 (C, NCOO), 160.5 (C, C5), 166.3 (C, CO2CH2CH3); HRMS 
(ESI), calcd for [C26H27
35
ClN2O4 + H
+
] 467.1732, found 467.1723. 
 
4.1.3. 1-(tert-butoxycarbonyl)-5-(4-chlorophenyl)-N-ethyl-1,2,3,4-
tetrahydrobenzo[h][1,6]naphthyridine-9-carboxamide 15a 
A suspension of ester 11a (2.54 g, 5.44 mmol) and KOH (85% purity, 1.08 g, 16.3 
mmol) in MeOH (140 mL) was stirred under reflux for 24 h. The resulting solution was 
cooled down at room temperature and concentrated under reduced pressure. The solid 
residue (3.35 g) was treated with a solution of HCl in Et2O (0.8 N, 138 mL, 110 mmol) 
and the resulting suspension was concentrated under reduced pressure to give the 
corresponding aminoquinolino carboxylic acid, in the form of hydrochloride, as a white 
solid (3.77 g). This crude product was used in the next step without further purification. 
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A solution of this crude product (3.60 g) in anhydrous CH2Cl2 (45 mL) was cooled to 0º 
C with an ice bath and treated dropwise with freshly distilled Et3N (2.89 mL, 2.10 g, 
20.7 mmol) and ClCO2Et (0.49 mL, 556 mg, 5.12 mmol). The resulting suspension was 
thoroughly stirred at 0 º C for 30 min and treated with EtNH2·HCl (0.42 g, 5.15 mmol). 
The reaction mixture was stirred at room temperature for 3 days, diluted with 10% aq. 
Na2CO3 (200 mL), and extracted with CH2Cl2 (3  300 mL). The combined organic 
extracts were washed with H2O (3  200 mL), dried over anhydrous Na2SO4, filtered 
and concentrated under reduced pressure to give a solid residue (2.36 g), which was 
purified through column chromatography (35-70 µm silica gel, hexane/EtOAc mixtures, 
gradient elution). On elution with hexane/EtOAc 60:40, amide 15a (1.22 g, 50% overall 
yield) was obtained as a white solid; Rf 0.23 (hexane/EtOAc 1:1). 
A solution of 15a (50 mg, 0.11 mmol) in CH2Cl2 (4 mL) was filtered through a 0.2 μm 
PTFE filter and evaporated at reduced pressure. The solid was washed with pentane (3  
4 mL) to give, after drying under standard conditions, the analytical sample of 15a (45 
mg) as a white solid: mp 203–204 °C (CH2Cl2); IR (ATR) ν 3391, 3316 (NH st), 1711, 
1687, 1654, 1639, 1617, 1597, 1583, 1568, 1532 (C=O, ArCC and ArCN st) cm–1; 
1
H NMR (400 MHz, CDCl3) δ 1.27 (t, J=7.2 Hz, 3H, CONHCH2CH3), 1.40 [s, 9H, 
C(CH3)3], 1.99 (br signal, 2H, 3-H2), 2.79 (t, J=6.4 Hz, 2H, 4-H2), 3.103.50 (br signal, 
2H, 2-H2), 3.54 (tt, J=7.2 Hz, J’≈5.2 Hz, 2H, CONHCH2CH3), 6.27 (t, J=5.2 Hz, 1H, 
CONHCH2CH3), 7.47 [ddd, J=8.4 Hz, J’≈J”≈2.0 Hz, 2H, 5ArC3(5)-H], 7.53 [ddd, 
J≈8.4 Hz, J’≈J”≈2.0 Hz, 2H, 5ArC2(6)-H],  7.96 (dd, J=8.4 Hz, J’=2.0 Hz, 1H, 8-H), 
8.08 (d, J≈8.4 Hz, 1H, 7-H), 8.25 (br s, 1H, 10-H); 13C NMR (100.6 MHz, CDCl3) δ 
14.9 (CH3, CONHCH2CH3), 24.0 (CH2, C3), 25.4 (CH2, C4), 28.0 [3CH3, C(CH3)3], 
35.1 (CH2, CONHCH2CH3), 44.8 (CH2, C2), 82.1 [C, C(CH3)3], 123.0 (C, C10a), 124.0 
(C, C4a), 124.2 (CH), 126.3 (CH) (C8 and C10), 128.6 [2CH, 5ArC3(5)], 129.9 (CH, 
C7), 130.3 [2CH, 5ArC2(6)], 131.4 (C, C9), 134.7 (C, 5Ar–C4), 138.3 (C, 5Ar–
C1), 145.4 (C, C10b), 148.0 (C, C6a), 154.0 (C, NCOO), 159.9 (C, C5), 167.0 (C, 
CONHCH2CH3); HRMS (ESI), calcd for [C26H28
35
ClN3O3 + H
+
] 466.1892, found 
466.1887. 
 
4.1.4. N-{{5-(4-chlorophenyl)-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-9-
yl}methyl}ethanamine 18a and 5-(4-chlorophenyl)-N-ethyl-1,2,3,4-
tetrahydrobenzo[h][1,6]naphthyridine-9-carboxamide 16a 
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A solution of amide 15a (0.65 g, 1.39 mmol) in anhydrous THF (32 mL) was cooled to 
0 ºC with an ice bath, and treated portionwise with LiAlH4 (0.17 g, 4.48 mmol). The 
resulting suspension was stirred under reflux overnight, cooled to 0 ºC with an ice bath 
and treated dropwise with 1N NaOH (20 mL), then diluted with H2O (25 mL), and 
extracted with EtOAc (3  30 mL). The combined organic extracts were dried over 
anhydrous Na2SO4, filtered and evaporated under reduced pressure to give a solid 
residue  (0.51 g), which was purified through column chromatography (35-70 µm silica 
gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient elution). On elution with 
CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, N-Boc-deprotected amide 16a (72 mg, 14% 
yield) was isolated as a yellowish solid. On elution with CH2Cl2/MeOH/50% aq. 
NH4OH 97:3:0.2 to 95:5:0.2, N-Boc-deprotected amine 18a (170 mg, 35% yield) was 
isolated as a yellowish solid; Rf(16a) 0.15 (CH2Cl2 /MeOH/NH4OH 9:1:0.05); Rf(18a) 0.49 
(CH2Cl2 /MeOH/NH4OH 9:1:0.05). 
A solution of 16a (64 mg, 0.17 mmol) in CH2Cl2 (5 mL) was filtered through a 0.2 μm 
PTFE filter and treated with a methanolic solution of HCl (0.75 N, 2.2 mL, 1.65 mmol). 
The resulting solution was evaporated at reduced pressure and the solid was washed 
with pentane (3  4 mL) to give, after drying under standard conditions, 16a·HCl (57 
mg) as a brown solid: mp 320–321 ºC (CH2Cl2 /MeOH  69:31); IR (ATR) ν 3500–2500 
(max at 3395, 3231, 3090, 3028, 2929, 2865, 2810, 2640, 
+
NH, NH, OH and CH st), 
1655, 1647, 1629, 1586, 1545 (C=O, ArCC and ArCN st) cm–1; 1H NMR (400 
MHz, CD3OD) δ 1.29 (t, J=7.2 Hz, 3H, CONHCH2CH3), 1.99 (tt, J≈J’≈6.0 Hz, 2H, 3-
H2), 2.75 (t, J≈6.0 Hz, 2H, 4-H2), 3.49 (q, J=7.2 Hz, 2H, CONHCH2CH3), 3.71 (t, J=5.6 
Hz, 2H, 2-H2), 4.84 (s, NH and 
+
NH), 7.66 [complex signal, 4H, 5ArC2(6)-H and 
5ArC3(5)-H], 7.85 (d, J≈9.2 Hz, 1H, 7-H), 8.24 (dd, J=9.2 Hz, J’=1.6 Hz, 1H, 8-H), 
8.86 (d, J=1.6 Hz, 1H, 10-H); 
13
C NMR (100.6 MHz, CD3OD) δ 14.8 (CH3, 
CONHCH2CH3), 20.0 (CH2, C3), 25.0 (CH2, C4), 36.2 (CH2, CONHCH2CH3), 43.0 
(CH2, C2), 109.8 (C, C4a), 116.2 (C, C10a), 120.9 (CH, C7), 123.6 (CH, C10), 130.4 
(2CH), 131.8 (2CH) [5ArC2(6) and 5ArC3(5)], 132.3 (C, 5Ar–C1), 132.5 (CH, 
C8), 133.8 (C, C9), 138.3 (C, 5Ar–C4), 140.2 (C, C6a), 151.5 (C, C5), 155.8 (C, 
C10b), 168.1 (C, CONHCH2CH3); HRMS (ESI), calcd for [C21H20
35
ClN3O + H
+
] 
366.1368, found 366.1364; Elemental analysis, calcd for C21H20ClN3O·HCl·H2O C 
60.01%, H 5.52%, N 10.00%, Cl 16.87%, found C 60.35%, H 5.81%, N 8.93%, Cl 
16.05%. HPLC purity: 94%.  
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A solution of 18a (106 mg, 0.30 mmol) in CH2Cl2 (8 mL) was filtered through a 0.2 μm 
PTFE filter and treated with a methanolic solution of HCl (0.75 N, 3.6 mL, 2.70 mmol). 
The resulting solution was evaporated at reduced pressure and the solid was washed 
with pentane (3  4 mL) to give, after drying under standard conditions, 18a·2HCl (96 
mg) as a yellowish solid: mp 323–324 ºC (CH2Cl2 /MeOH  69:31); IR (KBr) ν 3500–
2400 (max at 3379, 3198, 3095, 3028, 2926, 2863, 2767, 2667, 2552, 2422, 
+
NH, NH 
and CH st), 1639, 1587, 1504 (ArCC and ArCN st) cm–1; 1H NMR (400 MHz, 
CD3OD) δ 1.41 (t, J=7.6 Hz, 3H, 9-CH2NHCH2CH3), 1.99 (tt, J≈J’≈6.0 Hz, 2H, 3-H2), 
2.76 (t, J=6.0 Hz, 2H, 4-H2), 3.23 (q, J=7.6 Hz, 2H, 9-CH2NHCH2CH3), 3.73 (t, J=5.6 
Hz, 2H, 2-H2), 4.44 (s, 2H, 9-CH2NHCH2CH3), 4.84 (s, NH and 
+
NH), 7.67 [complex 
signal, 4H, 5ArC2(6)-H and 5ArC3(5)-H], 7.92 (d, J=8.8 Hz, 1H, 7-H), 8.06 (dd, 
J=8.8 Hz, J’=1.6 Hz, 1H, 8-H), 8.58 (d, J=1.6 Hz, 1H, 10-H); 13C NMR (100.6 MHz, 
CD3OD) δ 11.6 (CH3, 9-CH2NHCH2CH3), 20.0 (CH2, C3), 25.1 (CH2, C4), 43.0 (CH2, 
C2), 44.2 (CH2, 9-CH2NHCH2CH3), 51.5 (CH2, 9-CH2NHCH2CH3), 109.8 (C, C4a), 
116.7 (C, C10a), 121.7 (CH, C7), 126.0 (CH, C10), 130.4 (2CH), 131.8 (2CH) 
[5ArC2(6) and 5ArC3(5)], 131.0 (C, C9), 132.3 (C, 5ArC1), 135.5 (CH, C8), 
138.2 (C, 5ArC4), 139.1 (C, C6a), 151.4 (C, C5), 155.2 (C, C10b); HRMS (ESI) 
calcd for [C21H22
35
ClN3 + H
+
] 352.1575, found 352.1574; Elemental analysis, calcd for 
C21H22ClN3·1.5HCl·2.75H2O C 55.30%, H 6.41%, N 9.21%, Cl 19.43%, found C 
55.23%, H 6.16%, N 8.93%, Cl 19.10%. HPLC purity > 99%.   
 
4.2. Biological assays 
4.2.1. Determination of inhibitory effect on AChE and BChE activity 
The inhibitory activity against Electrophorus electricus (Ee) AChE (Sigma-Aldrich) 
and human serum BChE (Sigma-Aldrich) was evaluated spectrophotometrically by the 
method of Ellman et al. [15]. The reactions took place in a final volume of 300 L of 
0.1 M phosphate-buffered solution pH 8.0, containing EeAChE (0.03 u/mL) or hBChE 
(0.02 u/mL) and 333 M 5,5'-dithiobis(2-nitrobenzoic) acid (DTNB; Sigma-Aldrich) 
solution used to produce the yellow anion of 5-thio-2-nitrobenzoic acid. Inhibition 
curves were performed in duplicates using at least 10 increasing concentrations of 
inhibitors and preincubated for 20 min at 37 ºC before adding the substrate [28]. One 
duplicate sample without inhibitor was always present to yield 100% of AChE or BChE 
activities. Then substrates, acetylthiocholine iodide (450 M; Sigma-Aldrich) or 
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butyrylthiocholine iodide (300 M; Sigma-Aldrich), were added and the reaction was 
developed for 5 min at 37 ºC. The colour production was measured at 414 nm using a 
labsystems Multiskan spectrophotometer.  
Data from concentrationinhibition experiments of the inhibitors were calculated by 
non-linear regression analysis, using the GraphPad Prism program package (GraphPad 
Software; San Diego, USA), which gave estimates of the IC50 (concentration of drug 
producing 50% of enzyme activity inhibition). Results are expressed as mean  S.E.M. 
of at least 4 experiments performed in duplicate.  
The inhibitory activity against human recombinant AChE was also assessed using the 
method of Ellman  et al. [15]. Initial rate assays were performed at 37 °C with a Jasco 
V-530 double beam Spectrophotometer. The rate of increase in the absorbance at 412 
nm was followed for 240 s. AChE stock solution was prepared by dissolving human 
recombinant AChE (E.C.3.1.1.7) lyophilized powder (Sigma-Aldrich) in 0.1 M 
phosphate buffer (pH = 8.0) containing Triton X-100 0.1%. Stock solutions of inhibitors 
(1-3 mM) were prepared in methanol and diluted in methanol. Inhibitors were first 
screened at a single concentration (25 µM). Then, for compounds showing a percentage 
of inhibition higher than 50% at the screening concentration (25 µM), the IC50 values 
were determined. In this case, five/six increasing concentrations of the inhibitor were 
used, able to give an inhibition of the enzymatic activity in the range of 20-80%. The 
assay solution consisted of a 0.1 M phosphate buffer pH 8.0, with the addition of 340 
µM DTNB, 0.02 unit/mL of human recombinant AChE and 550 µM of substrate 
(acetylthiocholine iodide, ATCh). 50 L aliquots of increasing concentration of the 
tested inhibitor (or methanol) were added to the assay solution and pre-incubated with 
the enzyme for 20 min at 37 °C before the addition of the substrate. Assays were carried 
out with a blank containing all components except AChE in order to account for the 
non-enzymatic hydrolysis of the substrate. The reaction rates were compared and the 
percent inhibition due to the presence of inhibitor was calculated. Each concentration 
was analyzed in duplicate, and IC50 values were determined graphically from log 
concentration–inhibition curves (GraphPad Prism 4.03 software, GraphPad Software 
Inc.). Two/three independent experiments were performed for the determination of each 
IC50 value. 
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4.2.2. Kinetic inhibition studies  
To estimate the mode of inhibition of compound 16a and the corresponded benzylated 
analogue 14a, Lineweaver-Burk double reciprocal plots were constructed at relatively 
low concentration of substrate (0.11–0.55 mM) and using the same experimental 
conditions reported for the hAChE assay at section 4.2.1. The plots were assessed by a 
weighted least square analysis that assumed the variance of ν to be a constant 
percentage of ν for the entire data set. To confirm the mode of inhibition, Cornish-
Bowden plots were obtained by plotting S/v (substrate/velocity ratio) versus inhibitor 
concentration [21]. Data analysis was performed with GraphPad Prism 4.03 software 
(GraphPad Software Inc.). 
Calculation of the inhibitor constant (Ki) value was carried out by re-plotting slopes of 
lines from the Lineweaver-Burk plot versus the inhibitor concentration and Ki was 
determined as the intersect on the negative x-axis. K’i (dissociation constant for the 
enzyme-substrate-inhibitor complex) value was determined by plotting the apparent 1/ 
vmax, app versus inhibitor concentration [29]. 
 
4.2.3. Propidium displacement studies 
The affinity of selected inhibitors for the peripheral binding site of EeAChE (type VI-S, 
Sigma-Aldrich) was tested using propidium iodide (P) (Sigma-Aldrich), a known PAS-
specific ligand as previously described by Taylor et al. [22]. A shift in the excitation 
wavelength follows the complexation of propidium iodide and AChE [22a]. 
Fluorescence intensity was monitored by a Jasco 6200 spectrofluorometer (Jasco 
Europe, Italy) using a 0.5 mL quartz cuvette at room temperature. EeAChE (2 μM, 
assuming 82,000 molecular mass subunits) was first incubated with 8 μM propidium 
iodide in 1 mM Tris-HCl, pH 8.0 at room temperature. Stock solutions (4 mM) of each 
inhibitor were prepared in methanol. In the back titration experiments of the propidium-
AChE complex by the tested inhibitor, aliquots of inhibitor (2-40 μM, 4-68 μM and 2-
44 μM for 16a, 18a and 14a, respectively) were added successively, and fluorescence 
emission was monitored at 602 nm upon excitation at 535 nm. Blanks containing 
propidium alone, inhibitor plus propidium and EeAChE alone were prepared and 
fluorescence emission determined. Raw data were processed following the method of 
Taylor and Lappi [22b] to estimate KD values assuming a dissociation constant value for 
propidium for acetylcholinesterase from Electrophorus electricus equals to 0.7 μM [23]. 
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4.2.4. PAMPA-BBB assay 
To evaluate the brain penetration of the synthesized compounds, a parallel artificial 
membrane permeation assay for blood-brain barrier was used, following the method 
described by Di et al. [27]. The in vitro permeability (Pe) of fourteen commercial drugs 
through lipid extract of porcine brain membrane together with the test compounds was 
determined. Commercial drugs and the synthesized compounds were tested using a 
mixture of PBS:EtOH (70:30). Assay validation was made by comparing the 
experimental permeability of the different compounds with the reported bibliography 
values of the commercial drugs, which showed a good correlation: Pe (exp) = 1.4974 Pe 
(lit)  0.8434 (R2 = 0.9428). From this equation and taking into account the limits 
established by Di et al. for BBB permeation, we established the  ranges of permeability 
as  compounds of high BBB permeation  (CNS+): Pe (10
6
 cm s
1
) > 5.1; compounds of 
low BBB permeation (CNS): Pe (10
6
 cm s
1
) < 2.15, and  compounds of uncertain 
BBB permeation (CNS+/): 5.1 > Pe (10
6
 cm s
1
) > 2.15. 
 
4.3. Molecular modelling 
4.3.1. Setup of the system 
Molecular modelling was performed using the X-ray crystallographic structure of the 
recombinant human AChE (PDB ID: 3LII) [30]. The structure was refined by removal 
of N-acetyl-D-glucosamine and sulfate anions and addition of missing hydrogen atoms. 
Furthermore, the missing loop that comprises residues 259-263 (PGGTG) was modeled 
from the X-ray structure of hAChE complexed with huprine W (PDB ID: 4BDT) [31]. 
The enzyme was modeled in its physiological active form with neutral His447 and 
deprotonated Glu334, which together with Ser203 form the catalytic triad. The 
ionization state for the rest of ionizable residues was assessed from PROPKA3 
calculations [32]. Accordingly, the standard ionization state at neutral pH was 
considered but for residues Glu285, Glu450 and Glu452, which were protonated. 
Finally, three disulfide bridges were defined between Cys residues 257-272, 529-409, 
and 69-96, respectively. Structural waters were retrieved from those found in the AChE-
donepezil complex 1EVE [33]. 
Since Trp286 can adopt three main conformations in the peripheral binding site [9], 
three models were built up by re-orienting the side chain of Trp 286 as found in the X-
ray structures of the AChE complexes with propidium, bis(7)-tacrine and syn-TZ2PA6 
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(PDB ID: 1N5R, 2CKM and 1Q83, respectively). These models were energy minimized 
using the AMBER force field (see below). 
 
4.3.2. Docking 
Docking of AChE inhibitors was performed using the rDock program, which is an 
extension of the program RiboDock and utilizes an empirical scoring function calibrated 
on the basis of proteinligand complexes [24]. It is worth noting that previous studies 
strongly support the excellent performance of rDock for predicting the binding mode of 
a variety of AChE inhibitors to the enzyme gorge [9]. A cavity of radius 17 Å,
 
centered 
on the structure of a superligand containing huprine X, donepezil and propidium (as 
found in the X-ray structures 1E66 [34], 1EVE and 1N5R) was used to define the 
docking volume. Since huprine X and propidium are bound to the catalytic and 
peripheral binding sites, and donepezil is aligned along the gorge, this definition 
guarantees the exploration of the binding mode along the whole volume accessible for 
binding. Calculations were performed with no structural waters. Conformational 
flexibility around rotatable bonds of the ligand was allowed. Docking calculations were 
performed separately for the three models of the human enzyme, which differ in the 
relative orientation of the side chain of Trp286 (see above). Conformational adjustments 
of other residues in the binding site were accounted for indirectly by rescaling (by a 
factor of 0.9) the van der Waals volume of atoms. Each compound was subjected to 100 
docking runs and the poses were sorted according to its docking score. The top 50 best 
scored poses were clustered and further analyzed by visual inspection. 
 
4.3.3. Molecular dynamics simulations 
Molecular dynamics (MD) simulations were run to further check the stability of the 
proposed binding mode of AChE inhibitors. Starting from the initial poses obtained 
from docking calculations, a 100 ns MD simulation was performed using the PMEMD 
module of AMBER12 [35] software package and the parm99SB [36] force field for the 
protein and GAFF [37]-derived parameters for the ligand. The geometry of the ligand 
was optimized at the B3LYP/6-31G(d) level [38]. The charge distribution of the 
inhibitors was defined from the electrostatic charges determined by fitting the 
B3LYP/6-31G(d) electrostatic potential using the RESP procedure [39]. Na
+
 cations 
were added to neutralize the negative charge of the system with the XLEAP module of 
AMBER12. The system was immersed in an octahedral box of TIP3P water molecules 
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[40], preserving the crystallographic waters inside the binding cavity. The final system 
contained around 53,000 atoms.  
The geometry of the system was minimized in four steps. First, water molecules and 
counterions were refined through 7000 steps of conjugate gradient and 3000 steps of 
steepest descent algorithm. Then, the position of hydrogen atoms was optimized using 
4500 steps of conjugate gradient and 500 steps of steepest descent algorithm. At the 
third stage, hydrogen atoms, water molecules and counterions were further optimized 
using 11500 steps of conjugate gradient and 3500 steps of steepest descent algorithm. 
Finally, the whole system was optimized using 8500 steps of conjugate gradient and 
2500 steps of steepest descent algorithm. Thermalization of the system was performed 
in five steps of 25 ps, increasing the temperature from 50 to 298 K. Concomitantly, the 
residues that define the binding site were restrained during thermalization using a 
variable restraining force. Thus, a force costant of 25 kcal
.
mol
1.
Å
2
 was used in the first 
stage of the thermalization and was subsequently decreased by increments of 5 
kcal
.
mol
1.
Å
2
 in the next stages. Then, an additional step of 250 ps was performed in 
order to equilibrate the system density at constant pressure (1 bar) and temperature (298 
K). Finally, a 100 ns trajectory was run using a time step of 2 fs. SHAKE was used for 
those bonds containing hydrogen atoms in conjunction with periodic boundary 
conditions at constant volume and temperature, particle mesh Ewald for the treatment of 
long range electrostatic interactions, and a cutoff of 10 Å
 
for nonbonded interactions.  
The structural analysis was performed using in-house software and standard codes of 
AMBER12. The solvent interaction energies (SIE) technique developed by Purisima 
and co-workers was used to estimate the interaction free energies for the AChE 
inhibitors [26]. Calculations were performed for a set of 150 snapshots taken along the 
last 30 ns of the MD trajectory.  
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Appendix A. Supplementary material 
Supplementary data related to this article can be found at http://dx.doi.org/. These data 
include synthetic procedures and chemical characterization data of compounds 6a–c, 
8b, 9a–c, 10a–c, 11b, 12a,b, 13a, 14a, 16b, 17a, and 18b, additional results from the 
molecular modeling studies and PAMPA-BBB assay, as well as copies of the 
1
H and 
13
C NMR spectra and HPLC chromatograms of the tested compounds. 
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Table, Figure, and Scheme Legends 
 
Table 1. Inhibitory activity of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines against 
AChE and BChE. 
 
Table 2. Permeability values and predicted brain penetration of the novel 1,2,3,4- 
benzo[h][1,6]naphthyridines from the PAMPA-BBB assay. 
 
Fig. 1. Structure of the pyrano[3,2-c]quinoline derivative 1 and the peripheral site 
AChE inhibitor propidium iodide. 
 
Fig. 2. Lineweaver-Burk plots illustrating mixed-type inhibition of AChE-mediated 
acetylthiocholine hydrolysis by compound (A) 14a and (B) 16a. ATCh = 
acetylthiocholine; v = initial velocity rate. 
 
Fig. 3. (A) Back-titration of the propidium–AChE complex by compounds 16a, 17a, 
and 18a (2.0 μM EeAChE, 8.0 μM propidium, Tris HCl 1.0 mM , pH 8.0); (B) 
Determination of KD value for most active derivative 16a. KD value is calculated from 
the antilog of the Y-intercept value [22b]. P stands for propidium iodide and I stands for 
tested inhibitor; Fe is the initial fluorescence intensity when enzyme sites are saturated 
with P, FP is the fluorescence intensity when propidium is completely displaced from 
the enzyme, and F denotes the fluorescence intensity after adding a determined amount 
of displacing agent during the titration experiment. 
 
Fig. 4. (A) Representation of the binding mode of compound 16a (in orange) obtained 
at the end of the 100 ns MD trajectory. The side chains or backbone units of the 
residues involved in interactions are shown as green-colored sticks. Water molecules 
that mediate interactions of the ligand are shown as red spheres. Propidium is shown as 
grey sticks. (B) Superposition of the compounds 16a (orange) and 18a (cyan) as found 
at the end of the MD trajectories. 
 
 
Scheme 1. Synthesis of the target 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines. 
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Table 1 
Inhibitory activity of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines against AChE and 
BChE.
a
 
Compound EeAChE 
IC50 (μM) 
hAChE  
IC50 (μM) 
hBChE  
IC50 (μM) or  
% inhibition 
at 30 μM 
1st generation 
9a 5.21 ± 0.33 4.15 ± 0.16 8.41% 
9b > 30
b
 13.0 ± 0.8 4.42% 
9c 13.6 ± 1.8 > 25
c
 5.54% 
10a 6.33 ± 0.96 > 25
d
 8.68% 
10b 1.97 ± 0.17 1.06 ± 0.09 nd
e
 
10c 6.62 ± 0.62 > 25
f
 6.61% 
12a 0.281 ± 0.031 > 25
g
 20.3% 
13a > 30
h
 > 25
i
 12.4% 
14a 5.48 ± 0.51 0.801 ± 0.069 25.3% 
17a 0.147 ± 0.014 0.942 ± 0.038 nd
e
 
2nd generation 
12b 0.148 ± 0.017 22.8 ± 1.6 27.5% 
16a 0.046 ± 0.006 0.065 ± 0.003 0.92 ± 0.03 
18a 0.532 ± 0.030 0.556 ± 0.024 1.37 ± 0.07 
18b 2.15 ± 0.20 15.8 ± 0.9 2.59 ± 0.14 
Tacrine nd
e
 0.424 ± 0.021
j
 0.046 ± 0.003
j
 
Propidium nd
e
 32.3 ± 2.2
j
 13.2 ± 0.4
j
 
a
 IC50 inhibitory concentration (μM) of Electrophorus electricus or human recombinant 
AChE and IC50 inhibitory concentration (μM) or % inhibition at 30 μM of human serum 
BChE. IC50 values are expressed as mean ± standard error of the mean (SEM) of at least 
four experiments (n=4), each performed in duplicate. 
b
 43.7% Inhibition of EeAChE activity at 30 μM. 
c
 13.8% Inhibition of hAChE at 25 μM. 
d
 10.0% Inhibition of hAChE at 25 μM. 
e 
Not determined. 
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f
 15.7% Inhibition of hAChE at 25 μM. 
g
 17.8% Inhibition of hAChE at 25 μM. 
h
 33.7% Inhibition of EeAChE activity at 30 μM. 
i
 10.2% Inhibition of hAChE at 25 μM. 
j
 Data taken from ref [18], involving the same experimental conditions. 
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Table 2 
Permeability values and predicted brain penetration of the novel 1,2,3,4- 
benzo[h][1,6]naphthyridines from the PAMPA-BBB assay. 
Compound Pe (10
6
 cm s
1
)
a
 Prediction 
9a 13.3 ± 3.75 CNS+ 
9b 12.2 ± 1.54 CNS+ 
9c 16.8 ± 1.29 CNS+ 
10a 8.10 ± 1.13 CNS+ 
10c 9.50 ± 1.05 CNS+ 
12a 9.70 ± 1.03 CNS+ 
12b 14.6 ± 1.15 CNS+ 
13a 26.0 ± 3.87 CNS+ 
14a 7.70 ± 0.94 CNS+ 
16a 22.9 ± 0.78 CNS+ 
18a 5.60 ± 0.58 CNS+ 
18b 2.40 ± 0.73 CNS+/– 
a
 Values are expressed as the mean ± SD of three independent experiments. 
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